title: Pharmacologic therapy of ventricular arrhythmias.
abstract: To treat patients with ventricular arrhythmias properly, one must characterize the arrhythmia, define the underlying heart disease and look for and treat reversible causes. When arrhythmias are suitable for pharmacologic suppression, it is necessary to predefine therapeutic goals, then carefully document that the drug accomplishes these goals. Knowledge of a drug's metabolism, excretion, active metabolites and plasma protein binding is often required for full understanding of its clinical effect. Pharmacokinetic principles require that antiarrhythmic drugs be given on a rigid schedule and that plasma drug levels be frequently determined. Use of compartment models and the principle of superposition can enable one to achieve and maintain therapeutic drug concentrations while avoiding toxic side effects. The drugs commonly used to treat arrhythmias, lidocaine, propranolol, procainamide, diphenylhydantoin and quinidine, as well as some newer agents, have specific pharmacokinetics and toxic effects that must be understood.
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D006801:Humans; D007700:Kinetics; D008012:Lidocaine / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity; D008954:Models, Biological; D011342:Procainamide / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity; D011433:Propranolol / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity; D011802:Quinidine / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity
chemical_list: D000889:Anti-Arrhythmia Agents; D008012:Lidocaine; D011433:Propranolol; D011802:Quinidine; D011342:Procainamide